Stock NAVB NAVIDEA BIOPHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Navidea Biopharmaceuticals, Inc.

Equities

NAVB

US63937X2027

Market Closed - OTC Markets
Other stock markets
 03:21:18 2024-04-19 pm EDT 		5-day change 1st Jan Change
0.035 USD 0.00% Intraday chart for Navidea Biopharmaceuticals, Inc. -12.50% -36.59%
2023 Navidea Biopharmaceuticals, Inc. announced that it expects to receive $0.75 million in funding CI
2023 Navidea Biopharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Navidea Biopharmaceuticals, Inc. and Capital Royalty Partners II, L.P. Enter Binding Settlement Agreement and Mutual Release
AQ
Navidea Biopharmaceuticals, Inc. announced that it expects to receive $0.75 million in funding
CI
Navidea: Q3 Earnings Snapshot
AQ
Navidea Biopharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Navidea Biopharmaceuticals, Inc.(OTCPK:NAVB) dropped from S&P TMI Index
CI
Sector Update: Health Care
MT
Top Midday Decliners
MT
Navidea Biopharmaceuticals Says NYSE American Panel Upheld Delisting Decision
MT
Navidea Biopharmaceuticals, Inc. Announces NYSE American’s Decision to Suspend Trading In Its Common Stock
BU
Navidea Biopharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Navidea Biopharmaceuticals, Inc. NAVB Requests Oral Hearing With NYSE Hearing Panel
BU
Navidea Biopharmaceuticals, Inc. Announces Resignation of Malcolm G. Witter as Director, Member of the Audit Committee and Compensation, Nominating and Governance Committee of the Board
CI
Navidea Biopharmaceuticals, Inc. Announces NYSE American Has Commenced Delisting Proceedings and Intent to Appeal NYSE American Determination
AQ
Navidea Biopharmaceuticals, Inc. Presses Ahead, Embraces Opportunities
BU
Navidea Biopharmaceuticals, Inc. Announces NYSE American Has Commenced Delisting Proceedings and Intent to Appeal NYSE American Determination
BU
Navidea Biopharmaceuticals, Inc. Announces Executive Changes
CI
Navidea Biopharmaceuticals, Inc. Hires Craig A. Dais, CPA as Chief Financial Officer
BU
Navidea Biopharmaceuticals, Inc. Hires Craig A. Dais, CPA as Chief Financial Officer
CI
Navidea Biopharmaceuticals, Inc. Announces Board Changes
CI
Navidea Biopharmaceuticals, Inc. Welcomes Dana J Moss, JD to Board of Directors; Amit Bhalla Steps Down
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NAVB Stock
  4. News Navidea Biopharmaceuticals, Inc.